MedPath

a study to compare two treatment options for melasma.

Phase 4
Conditions
Health Condition 1: null- facial melasma
Registration Number
CTRI/2018/05/014062
Lead Sponsor
Pawan Gupta
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All consenting male and female patients diagnosed clinically with melasma

Exclusion Criteria

a)Pregnancy, lactation and females taking HRT/OCPâ??s

b)Any severe chronic medical illness,

c)Bleeding disorders or concomitant use of anticoagulants

d)Any medical treatment for melasma within 1 month of entry,

e)Hypersensitivity to TXA

f)Abnormal bleeding time, clotting time or platelet count

g)Refusal to allow photographs and Failure to finish the whole period of study would be excluded from the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
improvement in modified melasma area and severity index (mMASI).Timepoint: 4 weeks, 8 weeks and 12 weeks
Secondary Outcome Measures
NameTimeMethod
physicianâ??s global assessment and patient global assessment scales, and safety assessmentTimepoint: 12 weeks
© Copyright 2025. All Rights Reserved by MedPath